8-K: Current report filing
Published on December 20, 2007
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
___________________
FORM
8-K
___________________
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
Date
of
Report: December 17, 2007
(Date
of earliest event reported)
NOVELOS
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
333-119366
|
04-3321804
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
Number)
|
One
Gateway Center, Suite 504
Newton,
MA 02458
(Address
of principal executive offices)
(617)
244-1616
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers
On
December 17, 2007 the board of directors of Novelos Therapeutics, Inc. (the
“Company” or “Novelos”) appointed Joanne M. Protano to the position of Vice
President, Chief Financial Officer and Treasurer and appointed Kristin C.
Schuhwerk to the position of Vice President of Clinical Development, Operations.
In
connection with their appointments, Ms. Protano received an option to purchase
100,000 shares of the Company’s common stock and Ms. Schuhwerk received an
option to purchase 125,000 shares of the Company’s common stock. Both options
vest in equal annual installments over three years and have an exercise price
of
$0.451 per share which represents the closing price of the Company’s common
stock on December 17, 2007 as reported on the Over the Counter Bulletin Board.
Ms.
Protano succeeds George Vaughn, principal of Vaughn & Associates, P.C., as
Chief Financial Officer. Mr. Vaughn, who will continue to provide consulting
services to the Company, has served as the Company’s Chief Financial Officer on
a consulting basis from 2005 until the appointment of Ms. Protano.
Ms.
Protano, 39, has held the position of Senior Director of Finance and Controller
of the Company since June 2006. From 1996 to 2006, she held various management
and senior management positions with Ascential Software, Inc. and predecessor
companies including Assistant Controller, Reporting for Ascential Software,
Vice
President and Chief Financial Officer for the Ascential Software Division of
Informix Software, Inc. and Corporate Controller of Ardent Software, Inc. Prior
to her tenure in the technology industry, she was an audit manager with Deloitte
and Touche LLP, where she practiced as a certified public accountant from 1990
to 1996.
Ms.
Schuhwerk, 37, has been employed by the Company since July 2005 as
Director/Senior Director of Operations. Prior to her employment at Novelos,
she
worked in the biopharmaceutical industry managing and overseeing business
operations for multiple global Phase 2 and 3 clinical studies. From 2002 to
2005
she held the positions of Senior Project Manager and Director of Planning and
Business Operations in Clinical Development at Antigenics, Inc., a cancer
biotechnology company. From 1993 to 2002, she held research, project management
and management positions at Boston University Medical Center, Parexel
International, AstraZeneca and Brigham & Women’s Hospital.
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Dated: December 20, 2007 | NOVELOS THERAPEUTICS, INC. | |
| |
|
|
| By: | /s/ Harry S. Palmin | |
|
Name: Harry S. Palmin |
||
| Title: President and Chief Executive Officer | ||
3